A Phase 2 Open-label Multicenter Randomized Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with Resectable Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1)Cytologically and/or histologically-documented NSCLC: a) Stage I (> 2 cm) to IIIA (for subjects with N2 disease, only those with 1 single nodal station = 3 cm are eligible) NSCLC according to the 8th edition of American Joint Committee on Cancer staging classification b) Amenable to complete surgical resection c) Have not received any other therapy for this condition (chemotherapy, biologic or radiotherapy)

You may not be eligible for this study if the following are true:

  • 1) Subjects with small-cell lung cancer or mixed small-cell lung cancer 2) Subjects who require or may require pneumonectomy 3) Prior treatment with PD-L1, PD-L1, or CTLA-4 inhibitors 4) Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug. 5) Major surgical procedure within prior 30 days


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.